Tanja Fehm

RECENT SCHOLAR PUBLICATIONS

A longitudinal study of the subjective birth experience and the relationship to mental health
S Mrthesheimer, C Hagenbeck, M Helbig, P Balan, T Fehm, NK Schaal
BMC Pregnancy and Childbirth 25 (1), 1-17 2025



Detection of minimal residual disease and prediction of recurrence in breast cancer using a plasma-only circulating tumor DNA assay
W Janni, B Rack, TWP Friedl, AD Hartkopf, L Wiesmller, K Pfister, ...
ESMO Open 10 (4) 2025



Clinical validity of repeated circulating tumor cell enumeration as an early treatment monitoring tool for metastatic breast cancer in the PREDICT global pooled analysis
W Janni, TWP Friedl, TC Yab, FC Bidard, M Cristofanilli, DF Hayes, ...
Clinical Cancer Research 2025



CDK4/6-Inhibition: Sequenztherapien und die Suche nach den besten Biomarkern–ein berblick ber die aktuellen Programme
A Schneeweiss, SY Brucker, H Huebner, LL Volmer, CC Hack, K Seitz, ...
Senologie-Zeitschrift fr Mammadiagnostik und-therapie 22 (01), 43-58 2025



Die innovative Therapie des Mammakarzinoms–individualisiert und risikoadaptiert
T Fehm, W Budach, H Tesch, H Schmidberger
Die Onkologie 31 (3), 253-256 2025



Cell-free tumor DNA analysis in advanced or metastatic breast cancer patients: mutation frequencies, testing intention, and clinical impact
H Huebner, P Wimberger, E Laakmann, E Ruckhberle, M Ruebner, ...
Precision clinical medicine 8 (1), pbae034 2025



Hormone and HER2-receptor status in breast cancer: determination using sonographically guided core needle biopsy and correlation with excision specimen—a German single
M Pruss, JP Cieslik, J Trk, J Dobrowolski, M Neubacher, M Helbig, ...
Archives of Gynecology and Obstetrics, 1-11 2025



Characteristics and prognosis of patients with primary metastatic disease vs. recurrent HER2-negative, hormone receptor-positive advanced breast cancer
CB Walter, AD Hartkopf, A Hein, PA Fasching, HC Kolberg, P Hadji, ...
The Breast, 104412 2025



Calculating future 10-year breast cancer risks in risk-adapted surveillance: A method comparison and application in clinical practice
S Zachariae, AS Quante, M Kiechle, K Rhiem, TN Fehm, JG Schrder, ...
Cancer Prevention Research 18 (2), 85-92 2025



Liquid Biopsy beim Mammakarzinom-schneller reagieren, besser behandeln
B Behrens, T Fehm, JP Cieslik, N Krawczyk
InFo Hmatologie+ Onkologie 28 (1), 15-19 2025



Liebe Leserinnen und Leser
TN Fehm
Frauenheilkunde up2date 19 (01), 3-3 2025



Pharmacological Inhibition of MDM2 Induces Apoptosis in p53-Mutated Triple-Negative Breast Cancer
JL On, S Ghaderi, C Rittmann, G Hoffmann, F Gier, V Woloschin, JW Tu, ...
International Journal of Molecular Sciences 26 (3), 1078 2025



RAD51 Testing in Patients with Early HER2-Negative Breast Cancer and Homologous Recombination Deficiency: A Post Hoc Analysis of the GeparOLA Trial
G Villacampa, A Llop-Guevara, N Filmann, A Herencia-Ropero, ...
Clinical Cancer Research, OF1-OF7 2025



Axillary staging-New concepts
N Tauber, M Banys-Paluchowski, S Hartmann, T Reimer, F Fick, ...
ONKOLOGIE 2025



Axillres Staging–neue Konzepte
N Tauber, M Banys-Paluchowski, S Hartmann, T Reimer, F Fick, ...
Die Onkologie, 1-8 2025



Surrogate End Points for Overall Survival in Neoadjuvant Randomized Clinical Trials for Early Breast Cancer
F Conforti, V Nekljudova, I Sala, R Ascari, C Solbach, M Untch, C Denkert, ...
Journal of Clinical Oncology, JCO-24-01360 2025



Die Rolle der Liquid Biopsy beim primren und metastasierten Mammakarzinom
TN Fehm, C Leidinger, JP Cieslik, A Franken, B Behrens
Frauenheilkunde up2date 18 (06), 497-516 2024



Liquid Biopsy beim Mammakarzinom
TN Fehm, B Behrens, N Krawczyk
gynkologie+ geburtshilfe 29 (6), 46-53 2024



Update Mammakarzinom 2024 Teil 1–Expertenmeinungen zu Brustkrebs in fortgeschrittenen Krankheitsstadien
R Wrstlein, HC Kolberg, AD Hartkopf, TN Fehm, M Welslau, F Schtz, ...
Senologie-Zeitschrift fr Mammadiagnostik und-therapie 21 (04), 313-325 2024



Effects of Systematically Guided vs. Self-Directed Laparoscopic Box Training on Learning Performances: An Observational Study
M Neubacher, D Darici, N Krawczyk, M Arslan, M Pruss, T Fehm, I Beyer
Geburtshilfe und Frauenheilkunde 84 (12), 1135-1142 2024

MOST CITED SCHOLAR PUBLICATIONS

A pooled analysis of bone marrow micrometastasis in breast cancer
S Braun, FD Vogl, B Naume, W Janni, MP Osborne, RC Coombes, ...
New England journal of medicine 353 (8), 793-802 2005
Citations: 1699



Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study
T Kuehn, I Bauerfeind, T Fehm, B Fleige, M Hausschild, G Helms, ...
The lancet oncology 14 (7), 609-618 2013
Citations: 1660



Systemic spread is an early step in breast cancer
Y Hsemann, JB Geigl, F Schubert, P Musiani, M Meyer, E Burghart, ...
Cancer cell 13 (1), 58-68 2008
Citations: 1523



Circulating tumor cells in patients with breast cancer dormancy
S Meng, D Tripathy, EP Frenkel, S Shete, EZ Naftalis, JF Huth, PD Beitsch, ...
Clinical cancer research 10 (24), 8152-8162 2004
Citations: 1208



Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data
FC Bidard, DJ Peeters, T Fehm, F Nol, R Gisbert-Criado, D Mavroudis, ...
The lancet oncology 15 (4), 406-414 2014
Citations: 979



Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients
B Aktas, M Tewes, T Fehm, S Hauch, R Kimmig, S Kasimir-Bauer
Breast cancer research 11, 1-9 2009
Citations: 906



Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of
C Rdel, T Liersch, H Becker, R Fietkau, W Hohenberger, T Hothorn, ...
The lancet oncology 13 (7), 679-687 2012
Citations: 878



Early dissemination seeds metastasis in breast cancer
H Hosseini, MMS Obradović, M Hoffmann, KL Harper, MS Sosa, ...
Nature 540 (7634), 552-558 2016
Citations: 763



Circulating tumor cells predict survival in early average-to-high risk breast cancer patients
B Rack, C Schindlbeck, J Jckstock, U Andergassen, P Hepp, T Zwingers, ...
Journal of the National Cancer Institute 106 (5), dju066 2014
Citations: 710



HER-2 gene amplification can be acquired as breast cancer progresses
S Meng, D Tripathy, S Shete, R Ashfaq, B Haley, S Perkins, P Beitsch, ...
Proceedings of the National Academy of Sciences 101 (25), 9393-9398 2004
Citations: 689



Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer
G von Minckwitz, H Eidtmann, M Rezai, PA Fasching, H Tesch, ...
New England Journal of Medicine 366 (4), 299-309 2012
Citations: 625



Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial
S Riethdorf, V Mller, L Zhang, T Rau, S Loibl, M Komor, M Roller, ...
Clinical cancer research 16 (9), 2634-2645 2010
Citations: 609



Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant
T Fehm, A Sagalowsky, E Clifford, P Beitsch, H Saboorian, D Euhus, ...
Clinical cancer research 8 (7), 2073-2084 2002
Citations: 431



HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial
T Fehm, V Mller, B Aktas, W Janni, A Schneeweiss, E Stickeler, ...
Breast cancer research and treatment 124, 403-412 2010
Citations: 414



Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study
F Amant, G von Minckwitz, SN Han, M Bontenbal, AE Ring, J Giermek, ...
Journal of Clinical Oncology 31 (20), 2532-2539 2013
Citations: 408



Pooled analysis of the prognostic relevance of circulating tumor cells in primary breast cancer
WJ Janni, B Rack, LWMM Terstappen, JY Pierga, FA Taran, T Fehm, ...
Clinical Cancer Research 22 (10), 2583-2593 2016
Citations: 406



Treatment of breast cancer during pregnancy: an observational study
S Loibl, SN Han, G von Minckwitz, M Bontenbal, A Ring, J Giermek, ...
The lancet oncology 13 (9), 887-896 2012
Citations: 389



Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and
CS Schuetz, M Bonin, SE Clare, K Nieselt, K Sotlar, M Walter, T Fehm, ...
Cancer research 66 (10), 5278-5286 2006
Citations: 383



Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells
S Kasimir-Bauer, O Hoffmann, D Wallwiener, R Kimmig, T Fehm
Breast Cancer Research 14, 1-9 2012
Citations: 374



Effect of luteinizing hormone–releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study
B Gerber, G von Minckwitz, H Stehle, T Reimer, R Felberbaum, N Maass, ...
Journal of clinical oncology 29 (17), 2334-2341 2011
Citations: 345